UK markets open in 8 minutes
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,514.53 +307.40 (+1.69%) CRUDE OIL
79.09 +0.14 (+0.18%) GOLD FUTURES
2,309.60 0.00 (0.00%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,299.97 +1,398.93 (+3.05%)
Spruce Biosciences, Inc. (SPRB)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.7174 |
| Open | 0.7300 |
| Bid | 0.7313 x 200 |
| Ask | 0.7436 x 200 |
| Day's range | 0.7209 - 0.7498 |
| 52-week range | 0.6710 - 5.9500 |
| Volume | |
| Avg. volume | 1,384,368 |
| Market cap | 30.519M |
| Beta (5Y monthly) | 2.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Simply Wall St.
Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)
The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. ( NASDAQ:SPRB ), with the analysts...
- Zacks
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
Spruce Biosciences' (SPRB) CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH fails to meet the primary efficacy endpoint.
© 2024 Yahoo. All rights reserved.